过去三年来该群体在新型微生物药物研究中获得了可喜进展，预计有的部分会在未来产生重要影响。一是宿主-病原相互作用的研究进展明显，在病毒性肝炎研究中发现了我国的原创新药并试用于临床，是未来抗病毒耐药的重要方向；二是对肠道菌与药物关系的研究获得重要进展，天然药物直接作用于肠道菌，产生新药效的二级代谢产物；三是我国原创药物小檗碱经多年研究被批准进入临床，研究其对能量代谢性疾病等的疗效，希望形成我国原创大品种药物；四是肿瘤基础研究（乳腺癌靶点与通路）获得良好进展；五是在药物合成生物学研究中，以力达霉素为探针首次阐述了微生物二级代谢产物合成的启动调控（基因）和信号网络，为新型微生物药物的研发做了基础铺垫。.今后工作聚焦几个要点，一是耐药问题：研究耐药机理和抗菌新药，同时探究宿主与病毒相互作用，克服病毒耐药；二是探索肠道菌与药物相互作用；三是完成小檗碱的机理和临床研究，使其成为我国原创的治疗“三高”的一线药物，服务临床；四是探索克服癌症新思路，付诸药学实践；五是加强合成生物学研究，支持以上工作，并引出新概念微生物。

The research group is the major drug investigation group for infectious diseases in China. The goal of the team is to discover new-concept drugs for drug-resistant pathogens, as well as for major human diseases, like cancer and diabetes et al. Our research utilizes the knowledge generated from the cross-talks among medicine, pharmaceutical science, microbiology, chemistry, biotechnology and computational chemistry, et al, and the studies are very time-consuming, as most of the matured successes require human study in clinic. The team leaders encourage research ctivities characterized with fresh idea and translational potential, aiming for solutions for human major health problems. In the past 3 years, the group has made significant progresses in the following fields. 1) The research on the interaction between host and viruses has revealed several cellular proteins that were important for the.replication of hepatitis viruses (HCV and HBV), and our innovative drugs that working through the host proteins are currently in clinical investigation for hepatitis C patients. 2) We have discovered that gut microbiota were very important for chemical drugs given in oral route, considering that chemical structures could be modified by enzymes of the gut flora, and production of secondary metabolites by the intestinal bacteria could be regulated via treating with drugs. 3) Berberine has been approved by the CFDA for clinical trials in patients suffer from the metabolic syndromes, after illustrating molecular mechanisms of the drug in our group. 4) Success has also been made in cancer molecular biology, especially for breast cancer (in autophagy and EMT), of which novel signal pathways and regulations have been identified. 5) . Through analyzing bacterial gene clusters that participates the synthesis of antibiotics, we have identified a chemical/biological mechanism that triggers and controls the synthesis of lidamycin, which is a novel anticancer antibiotic from our group and now in the phase II clinical trial in China. In the past 3 years, the group has published 71 SCI articles, submitted 27 patent applications and obtained 14 patent grants. One innovative drug candidate (for metabolic syndromes) has been approved for clinical study, and another one for HCV infection has been submitted to the CFDA. Currently, the group has 4 innovative drug candidates in clinical trials in China, and other 2 will be ready for clinical trial application soon. The laboratory development is in its good time, which is demonstrated with multiple national programs, mega-projects and international collaborations between China and US (or European countries). Future activity will be centered on novel drugs against drug-resistant bacteria, host-virus interaction targeting drug-resistant viruses (such as HBV, HCV and influenza), interaction between gut microbiota and orally given drugs, novel cancer drugs or drug targets, as well as synthetic biology for pharmaceutical science.